Director US Health Economic Value Access & Strategy (HEVAS)

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. Overview In the US Cell & Gene (CGT) Marketplace, the payer is not only our Commercial and Government Health Plans, but also the Formulary Decision Makers within our Authorized Treatment Centers (ATCs) who are evaluating the financial viability of our therapies against all other Cell & Gene therapies (CGTs). Iovance is seeking Health Economic Value Access and Strategy (HEVAS) Director as a part of the US Market Access function to develop and translate economic evidence into value-based messaging and will be responsible for developing payer resources, billing & coding guides and patient support in alignment with our value proposition. This individual will understand Payer, hospital and provider clinic evaluation and financial feasibility to support the US Payer field team with pre-approval market readiness (FDAMA 114), cost of care / site of care and cost-effectiveness for our key formulary decision makers. This Market Access leader will partner cross-functionally to identify pricing strategies for our approved and pipeline therapies by understanding the US Cell and Gene Market environment needs, impact to GTN, and risk for price erosion. This is an individual contributor role with strategic leadership responsibility and no direct people management. Essential Functions and Responsibilities Partner with Policy and Payer Marketing on engagement strategy with external partners and formulary decision-makers primarily in national/regional health plans, CMS, integrated delivery networks (IDNs), ATCs, Large physician groups (LPGs) Owns the development and execution of payer resources, reimbursement resources, end-to-end payer and channel marketing; provides resources to support the market access field team and pull through strategies Build and drive the US value proposition story for AMTAGVI and pipeline therapies to include but not limited to impact of complete and partial responses on PROs, productivity and future treatment costs and pharmacoeconomic impact of evolving treatment patterns Incorporate health economics, business analytics and competitive intelligence into the development of innovative strategies to gain, improve and defend public and private market access, specifically, pricing (and contracting) strategic planning within Market Access to create innovative proposals to meet public and private payer needs Directs the strategy and maintenance of formulary submission packages, total cost of care US models and other economic modeling and healthcare resource use analyses Support field-based cross-functional teams to provide pharmacoeconomic expertise in access engagements Manages operations and ensures compliance of Iovance Pricing Committee, GTN implications review and update charter and plan agendas to drive development of Committee recommendations Assess clinical and economic data gaps at key accounts and collaborate with internal stakeholders: Medical, Policy, Reimbursement HEOR, Payer Accounts, Marketing, Legal to provide insight into health economic value needs Support Market Access Account team(s) with Payer and Formulary Decision Makers at key congresses, such as PCMA, AMCP, ASTCT as needed Work cross functionally as a liaison with the brand teams to develop, implement, and communicate strategies and tactics to ensure alignment within the Market Access team on key cross-functional priorities Partnering with Commercial Strategy on Market